Detección y caracterización de autoanticuerpos anti-ZnT8 en pacientes argentinos con diabetes mellitus tipo 1

Faccinetti, Natalia Ines; Rovitto, Bruno David; Guerra, Luciano; Sabljic, Adriana Victoria; Iacono, Rubén Francisco; Trifone, Liliana; Poskus, Edgardo; Trabucchi, Aldana; Valdez, Silvina

doi:10.1016/j.raem.2016.09.001

Cited by 1 publication

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the latest antibodies investigated in human medicine with an impact on DM are the ones against zinc transporter isoform 8 (ZnT8), a molecule that transports zinc from the cytoplasm into the insulin secretion granule, thus allowing the hexameric conformation of insulin and its subsequent excretion. In humans, improved prediction of DM has been achieved from 90%, with the measurement of anti-GAD 65, anti-IA-2, and anti-IAA autoantibodies, to 96% with the addition of anti-ZnT8 antibody [ 11 ]. This transporter protein has been found in the pancreas of canines, presenting the same genomic organization between humans and canines, as they share 98% of conserved amino acids and 70% of residues [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Determination of autoantibodies in dogs with diabetes mellitus

González

Pérez-Bravo

2021

Vet World

View full text Add to dashboard Cite

Background and Aim: The classification of diabetes mellitus (DM) in dogs has been controversial as currently canine insulin-dependent DM is classified together with absolute insulin deficiency, non-insulin-dependent DM, and relative insulin deficiency. Studies on human autoantibodies evaluated in canines with DM, such as anti-glutamic acid decarboxylase (GAD65), anti-islet antigen 2 (IA2), and anti-zinc transporter isoform 8 (ZnT8), have been inconclusive. Thus, this study was designed to establish the serological profile of anti-GAD65, anti-IA2, and anti-ZnT8 antibodies in a group of dogs with and without DM. Materials and Methods: Sixty-one dogs, including 31 patients with DM (with and without insulin treatment) and 30 patients without DM (normal weight and obese), were included for determining autoantibodies using a human enzyme-linked immunosorbent assay (ELISA) detection system for type 1 DM. Results: This study found the presence of anti-IA2 antibodies in 58% of the sample (18/31 patients with DM); however, the presence of anti-GAD65 was not detected, and anti-ZnT8 was found in 3 (9.6%) patients with DM. Conclusion: This study showed a higher positive frequency of anti-IA2 antibodies in a sample of canine with DM, indicating that alterations in the signaling vesicle tyrosine phosphatase 2 lead to lower insulin release and thus to an increase in patients' glycemia. These preliminary results should be taken with caution and corroborated by a canine-specific assay when an ELISA is available for such determination.

show abstract

Section: Introductionmentioning

confidence: 99%